AstraZeneca’s Post

Our latest study reveals significant barriers patients encounter in comprehending their diagnosis, primarily due to insufficient information, education, and support. These challenges hinder their ability to self-advocate and participate effectively in shared decision-making. To address these issues, the study recommends several actions: - Enhance Communication: Improve the effectiveness of communication between healthcare professionals (HCPs) and patients. - Empower Patients: Provide patients with the necessary information and guidance to advocate for themselves. - Activate Advocacy Groups: Mobilize local patient advocacy groups to drive change and promote patient advocacy. For more detailed insights, visit the link below.

Our Precision Prostate Cancer Pathway allows for confident decision-making between you and your patient by enhancing the current standard of care. Download our pathway brochure to learn more about the three biomarker tests to improve patient care. https://ow.ly/RbJv50PBHIg

Early diagnosis is key to improving cancer survival rates because survival rates are just 10% when cancer is diagnosed at a late stage, but as high as 90% when diagnosed at an early stage. Xgenera has developed a revolutionary blood-based, multi-cancer diagnostic test called miONCO. Utilising a panel of biomarkers and artificial intelligence to identify 12 cancers simultaneously across any stage, with an accuracy of 99% and with an ultra-low false positive rate, miONCO presents the opportunity for substantial positive impact beyond current best practice. Find out more about Xgenera here: https://ow.ly/CH0F50PwGOl

A unique and interesting study in order to understand the challenges people with metastatic breast cancer face when learning about their biomarkers. One of the conclusion is that policy makers and their governments, healthcare professionals and their societies, patient advocates and their organisations, global health organisations, and pharmaceutical and diagnostic companies worldwide should work together to improve communication and understanding of biomarkers to patients with mBC. It is only through collaboration and concerted effort that change can be realised for the millions of people living with mBC today.

A simple blood test that can detect and monitor cancer is becoming a reality, thanks to liquid biopsies. Welcome to our brand new Liquid Biopsies and Companion Diagnostics feature. Discover how automation in the field is transforming cancer care, how assay development times are being cut, and how innovative methods are doubling cfDNA yields. #liquidbiopsy #diagnostics #labautomation #cancerdiagnostics #cancerresearch

Interested in the future of cancer diagnostics? Our recent, critically acclaimed webinar delved into liquid biopsy assays, essential for early cancer detection using blood samples. Exciting news! We've crafted a blog to distill this invaluable knowledge. Read our blog to discover why accuracy in these tests is crucial for personalized treatment. Explore real-world case studies and key Q&A discussions. Ready to explore? Read our latest blog: Webinar Overview: Challenges of Liquid Biopsy Assay Validation and Quality Control https://hubs.ly/Q02wJGR50 #LiquidBiopsy #CancerDetection #PrecisionMedicine

🎗️ ️ 𝐸𝓂𝓅𝑜𝓌𝑒𝓇𝒾𝓃𝑔 𝐵𝓇𝑒𝒶𝓈𝓉 𝒞𝒶𝓃𝒸𝑒𝓇 𝒫𝒶𝓉𝒾𝑒𝓃𝓉𝓈 & 𝒞𝓁𝒾𝓃𝒾𝒸𝒾𝒶𝓃𝓈 🎗️ Today marks a significant step forward. We're excited to introduce our new landing page, designed to simplify the intricate realm of molecular testing for breast cancer prognosis and chemotherapy benefit prediction. https://bit.ly/45CDOkl Our mission? To equip patients with vital insights before undergoing the EndoPredict test and to clarify how these results play a pivotal role in treatment decisions. Join us in this journey of empowerment and share with us: How do you communicate the benefits of genomic testing to your breast cancer patients? #BreastCancerAwareness #CancerTreatment #PrecisionMedicine

CDK4/6 inhibitors are providing positive results for patients with breast cancer. Our AJMC - The American Journal of Managed Care Peer Exchange features valuable insights on the patient journey, biomarker testing, payer considerations, treatment adoption, and future developments. #breastcancer #AJMCpeerexchange

ANGLE breakthrough provides deeper, personalised insights on cancer progression https://lnkd.in/euurJuFG

Black men are disproportionately affected by #ProstateCancer, with incidence 64% higher than white men in the United States. During #ProstateCancerAwarenessMonth, learn more about the signs and symptoms of prostate cancer, and review ZERO Prostate Cancer’s doctor discussion guide to learn which questions to ask if you’ve received a prostate cancer diagnosis. https://bit.ly/48kkGu9